发明名称 |
Composition comprising expression or activity regulators of AKAP12 for treating central nerve system diseases |
摘要 |
The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury. |
申请公布号 |
US9089554(B2) |
申请公布日期 |
2015.07.28 |
申请号 |
US201214000587 |
申请日期 |
2012.02.21 |
申请人 |
SNU R&B Foundation |
发明人 |
Kim Kyu-Won;Cha Jong-Ho |
分类号 |
A01N37/18;A61K38/00;A61K39/395;C12N15/113 |
主分类号 |
A01N37/18 |
代理机构 |
Riverside Law LLP |
代理人 |
Riverside Law LLP |
主权项 |
1. A method of reducing inflammation-induced secondary injury in the central nervous system of a subject in need thereof by forming fibrotic-glial scars, the method comprising administering to the subject a composition comprising a pharmaceutically effective amount of TGF-β1 (transforming growth factor-beta 1) and retinoic acid as an activator of AKAP 12 (A-kinase anchoring protein 12) under oxygenated conditions to form fibrotic-glial scars, wherein the subject's level of inflammation-induced secondary injury is reduced following administration of TGF-β1 and retinoic acid compared to the subject's level of inflammation-induced secondary injury in the absence of TGF-β1 and retinoic acid. |
地址 |
Seoul KR |